

FRESH THINKING ABOUT THE NEWEST ADVANCES STARTS HERE

PROGRAM HIGHLIGHTS

This seminar series focuses on the key challenges of diagnosis and treatment of chronic liver disease; current and emerging pharmaceutical and surgical therapies and the best knowledge to improve patient outcomes

- ▶ Updated content based on the latest medical guidelines and clinical trial results
- ▶ Strong patient-focused educational sessions using evidence-based studies from the latest AASLD, EASL and DDW programs
- ▶ Local experts from each city providing an interdisciplinary, team approach to treatment
- ▶ Participants can receive up to **6.0 AMA PRA Category 1 Credits™** or up to **7.3 nursing education** credits

WHO SHOULD ATTEND?

This program was developed for Gastroenterologists, Internists, Hepatologists, and Family Physicians as well as Advanced-practice Providers, Clinical Pharmacists and Nurse Specialists.

THE BENEFITS OF PARTICIPATION

- ▶ Acquire countless practice 'pearls' from the nation's top liver disease specialists
- ▶ Validate or Challenge long-standing patient care assumptions
- ▶ Participate with local colleagues on tough clinical cases
- ▶ Access the clinical resources and referral options in your community
- ▶ **Increase your confidence to better manage patients with advancing liver disease**



WASHINGTON, DC

Embassy Suites Alexandria

Coleman Smith, MD
Georgetown University School of Medicine
Kirti Shetty, MD
University of Maryland School of Medicine
Brian Lam, PA-C
Inova Fairfax Hospital



NEW ORLEANS, LA

Hyatt Centric French Quarter

Fredric G. Regenstein, MD
Tulane University School of Medicine
Shobha Joshi, MD
Ochsner Clinic Foundation
Elizabeth Britton, ARPN
Louisiana Department of Health



AUGUST 22

PHOENIX, AZ

Black Canyon Conference Center

Hugo Vargas, MD, MS
Mayo Clinic - Scottsdale
Richard Manch, MD
Arizona Liver Health
Ann Moore, FNP-C
Arizona Liver Health



SEPTEMBER 12

DETROIT, MI

DoubleTree Hotel Novi

Robert Fontana, MD
University of Michigan
Dilip Moonka, MD
Henry Ford Health System
Jeffrey P. McMahon, PA-C
Henry Ford Health System



SEPTEMBER 26

SAN DIEGO, CA

Marriott La Jolla

Catherine Frenette, MD
Scripps Health
Mazen Nourredin, MD
Cedars Sinai Medical Center
Lisa Richard, PA-C
University of California, San Diego



OCTOBER 3

DALLAS, TX

Embassy Suites - Dallas Park Central

Jacqueline O'Leary, MD
Dallas VA Medical Center
Amit Singal, MD
UT Southwestern Medical Center
Jordan Mayberry, PA-C
UT Southwestern Medical Center

FUTURE EVENTS

Denver, CO October 10
Ft. Lauderdale, FL October 17

For more information, see
<http://bit.ly/liver2020>

Non-Profit Org.
U.S. Postage
Paid
Louisville, Ky.
Permit No. 769

UNIVERSITY OF
LOUISVILLE
Continuing Medical Education &
Professional Development
University of Louisville
Louisville, KY 40292

**EMERGING
THERAPIES**

for PBC, NASH, ESLD and HCC

2020

Completely Updated for 2020

Available as a Live, In-Person
seminar or a Web-based
educational program

Updated Course Calendar - See inside

EMERGING THERAPIES

for PBC, NASH, ESLD and HCC

An Evidence-Based Seminar Focused on
Chronic Liver Diseases



COVID-19 Precautions at Our Seminars

The health and safety of our course participants is paramount and we have implemented a host of CDC recommendations including:

- ▶ Meeting spaces and equipment will be thoroughly disinfected before the sessions begin.
- ▶ Hand-sanitizing stations in our meeting rooms.
- ▶ Seating will include appropriate distancing and we will limit the total number of participants - inclusive of faculty, staff and exhibitors.
- ▶ Protective masks will be made available for you.
- ▶ All hotel banquet staff will wear protective gloves and face masks.
- ▶ Food and beverage areas will be cleaned and sanitized regularly throughout the day.
- ▶ Appropriate packaging and protective barriers at food and beverage stations.

IMPROVE YOUR Knowledge | Competence | Confidence

SEMINAR OVERVIEW

This seminar series will provide updates on the diagnosis and treatment of chronic liver disease with a focus on patient care and symptom management. Location-specific faculty experts deliver state-of-the-art material in a setting that stresses interaction.

The seminar will concentrate on key diseases of the liver and address the latest diagnosis, treatment and care management approaches for each.

NEW for 2020: Hepatology Updates: Breaking news on Autoimmune Hepatitis, Transplant of HCV+ organs, Hepatorenal Syndrome, the Resurgence of Hepatitis A and other emerging topics.

This seminar is also available in an online format.
See <http://bit.ly/liver2020> for more details.

COVID-19 Precautions at Our Seminars

The health and safety of our course participants is paramount and we have implemented a host of CDC recommendations including:

- ▶ Meeting spaces and equipment will be thoroughly disinfected before the sessions begin.
- ▶ Hand-sanitizing stations in our meeting rooms.
- ▶ Seating will include appropriate distancing and we will limit the total number of participants – inclusive of faculty, staff and exhibitors.
- ▶ Protective masks will be made available for you.
- ▶ All hotel banquet staff will wear protective gloves and face masks.
- ▶ Food and beverage areas will be cleaned and sanitized regularly throughout the day.
- ▶ Appropriate packaging and protective barriers at food and beverage stations.

WHY SHOULD YOU PARTICIPATE?

- ▶ **UPDATE** your clinical knowledge with expert faculty and internationally recognized studies
- ▶ **VALIDATE** your clinical decision processes and patient care approaches
- ▶ **COLLABORATE** with local colleagues to discuss new diagnostic and treatment options

PROGRAM AGENDA

7:30 am	Registration, Continental Breakfast & View Exhibits
8:00 am	Opening Comments and Pre-Test
8:20 am	<p>End Stage Liver Disease: Treatment, Managing Complications and Transplant</p> <ul style="list-style-type: none"> ▶ Staging, workup, and diagnosis of cirrhosis <p>Liver Transplantation</p> <ul style="list-style-type: none"> ▶ Listing criteria, MELD scores, exceptions and the transplant process <p>Case Study 1 – Cirrhosis and Encephalopathy</p>
9:25 am	<p>Hepatocellular Carcinoma (HCC)</p> <ul style="list-style-type: none"> ▶ Screening diagnostic serum assays and imaging tests ▶ Treatment and management options: Ablation, TACE and Surgery
10:00 am	Break & View Exhibits
10:15 am	<p>Hepatocellular Carcinoma: New Systemic Treatment Options</p> <ul style="list-style-type: none"> ▶ New chemotherapy regimens in development and testing ▶ Immunotherapy as the new MoA for HCC <p>Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma</p>
11:00 am	<p>Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis</p> <ul style="list-style-type: none"> ▶ Epidemiology of PSC and Improving survival in PSC patients ▶ Causes and markers of PBC ▶ Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
11:40 am	<p>Hepatology Update I – Viral Hepatitis</p> <ul style="list-style-type: none"> ▶ The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs
12:15 pm	Luncheon Presentation and View Exhibits
1:10 pm	<p>Hepatology Update II – Emerging Topics in Liver Disease</p> <ul style="list-style-type: none"> ▶ Alcoholic Liver Disease, Liver disease and Pregnancy, Hepatorenal syndrome
1:40 pm	<p>NAFLD, LAL-D and NASH</p> <ul style="list-style-type: none"> ▶ Epidemiology, Demographics, Diagnosis and Treatment
2:15 pm	Break & View Exhibits
2:30 pm	<p>NASH Treatments in Practice and in Development</p> <ul style="list-style-type: none"> ▶ Current therapies for fatty liver disease including life style changes ▶ Therapies in clinical development for NASH <p>Case Study 3 – NASH Diagnosis and Treatment</p>
3:30 pm	Post-test and Wrap-Up
3:40 pm	Adjourn

EDUCATIONAL OBJECTIVES

After attending this activity, participants should be able to:

- ▶ Summarize the causes of chronic liver disease and hepatic encephalopathy
- ▶ Comprehend the complexities of organ transplant procedures and waitlists
- ▶ Review the current therapies for PBC and clinical approaches for PSC
- ▶ Discover diagnostic tests for Fatty Liver Disease that may soon be in daily use
- ▶ Discuss the importance of liver biopsy for assessment of liver disease as well as less invasive tools and procedures
- ▶ Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number
- ▶ Discover why Immunotherapy is the new Method of Action for liver cancer
- ▶ Discuss treatment options for thrombocytopenia; including therapeutic alternatives to platelet transfusion
- ▶ Analyze current clinical cases to improve diagnostic and treatment skills

COURSE DIRECTORS

Paul Pockros, MD, FACP

Director, Liver Disease Center
Scripps Clinic
Director, SC Liver Research Consortium

Catherine Frenette, MD

Medical Director for Liver Transplantation
Scripps Center for Organ and Cell Transplantation

REGISTRATION INFORMATION

	Early Registration	Regular Registration
Physicians, Clinical Pharmacists and Administrators	\$95	\$115
Nurses, Nurse Practitioners and PA's	\$70	\$90
Medical Residents & Fellows	\$60	\$80

To Register & For More Information: <http://bit.ly/liver2020>

Or call: University of Louisville CME & PD (502) 852-5329

Early Registration ends Wednesday prior to program date.

Regular Registration begins Thursday prior to through program date.

Cancellation Policy: Requests for cancellation must be submitted to cmepd@louisville.edu at least seven (7) days prior to the program. Such requests will receive a full refund less a \$20 processing fee.

ACCREDITATION

Joint Provider Statement



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortium. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

DESIGNATION STATEMENT

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

Nurse Practitioners & Physician Assistants - AANP and AAPA accept Category I credit from **AMA PRA Category 1 Credit(s)**[™] organizations accredited by ACCME.

SPONSORS



The mission of the **University of Louisville** Continuing Medical Education and Professional Development program is to facilitate the needs of physicians and other healthcare team members as they seek self-improvement through life-long learning. For more information visit <http://louisville.edu/medicine/cme>



The **SC Liver Research Consortium (SCLRC)** is an organization of physicians specializing in hepatology and gastroenterology clinical research. SCLRC's mission is to team research sponsors and SCLRC's over 90 research sites together to provide faster, higher-quality research results compared to the current "conventional" sponsor-site arrangement. For more information visit www.scliver.com

DISCLOSURE

Commercial Support

This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. At the time this brochure was developed, a complete listing of commercial supporters is not available. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. Disclosure will be made to all participants at the conference location, prior to the commencement of the educational activity.